 Cardiac disturbances administration taxol clinical development taxol new antimicrotubule agent unique mechanism cytotoxic action due serious hypersensitivity reactions HSRs supply large-scale phase II trials taxol impressive activity advanced cisplatin-refractory ovarian carcinoma incidence HSRs premedications modifications administration schedule various manifestations potential cardiotoxicity several patients phase II studies taxol Asymptomatic bradycardia high proportion patients ovarian cancer patients doses taxol phase II study profound cardiac disturbances range atrioventricular conduction blocks bundle branch block ventricular tachycardia VT manifestations cardiac ischemia patients taxol Descriptions events report investigators potential adverse effects disturbances serious sequelae patients investigators high degree caution precise risk factors frequency clinical significance adverse cardiac effects